Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.

[1]  P. Hari,et al.  A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Prince,et al.  The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation. , 2014, Clinical lymphoma, myeloma & leukemia.

[4]  J. McGuirk,et al.  Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation , 2014, Bone Marrow Transplantation.

[5]  J. Vose,et al.  Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Einsele,et al.  Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Perazella,et al.  Reviews: Recognition, Treatment, and Prevention of Propylene Glycol Toxicity , 2007, Seminars in dialysis.

[8]  M. Mullins,et al.  Osmol Gap as a Surrogate Marker for Serum Propylene Glycol Concentrations in Patients Receiving Lorazepam for Sedation , 2006, Pharmacotherapy.

[9]  K. Wilson,et al.  Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. , 2005, Chest.

[10]  J. Fish,et al.  Propylene Glycol‐Associated Renal Toxicity from Lorazepam Infusion , 2003, Pharmacotherapy.

[11]  A. Goldman.  Issues in designing sequential stopping rules for monitoring side effects in clinical trials. , 1987, Controlled clinical trials.

[12]  J. Rossi,et al.  Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies , 2004, Cancer Chemotherapy and Pharmacology.